Compounds effecting glucokinase
Compounds effecting glucokinase
United States Patent 7,390,908
Boyd , et al. June 24, 2008
Abstract
The invention relates to the use of a compound of Formula (I) or a salt, solvate or prodrug thereof, wherein R.sup.1, R.sup.2, R.sup.3, n and m are as described in the specification, in the preparation of a medicament for the treatment or prevention of a disease condition mediated through glucokinase (GLK), such as type 2 diabetes. ##STR00001## The invention also relates to a novel group of compounds of Formula (I) and to methods for preparing compounds of Formula (I).
Inventors: Boyd; Scott (Cheshire, GB), Caulkett; Peter William Rodney (Cheshire, GB), Hargreaves; Rodney Brian (Cheshire, GB), Bowker; Suzanne Saxon (Cheshire, GB), James; Roger (Congleton, GB), Johnstone; Craig (Cheshire, GB), Jones; Clifford David (Cheshire, GB), McKerrecher; Darren (Cheshire, GB), Block; Michael Howard (Waltham, MA)
Assignee: AstraZeneca AB (Sodertalje, SE)
Appl. No.: 10/486,496
Filed: August 15, 2002
PCT Filed: August 15, 2002
PCT No.: PCT/GB02/03745
371(c)(1),(2),(4) Date: October 18, 2004
PCT Pub. No.: WO03/015774
PCT Pub. Date: February 27, 2003
